755033-91-1

Upstream product

• 34819-86-8 3,4-di-O-acetyl-6-deoxy-L-glucal 
• 54621-88-4 4-O-acetyl-2,3,6-trideoxy-L-erythro-hex-2-enono-1,5-lactone 
• 473811-80-2 (2S,3S)-5-acetoxy-6-methyl-5,6-dihydropyran-2-one 
• 54826-92-5 (5R,6S)-5,6-dihydro-5-hydroxy-6-methylpyran-2-one 
• 941703-48-6 C₈H₁₀O₅ 
• 108-98-5 thiophenol 
• 179913-38-3 1,4-di-O-acetyl-3-azido-2,3,6-trideoxy-L-lyxo-hexopyranose 

Downstream Products

• 849071-47-2 phenyl 3-azido-2,3,6-trideoxy-1-thio-L-lyxo-hexopyranoside 
• 849071-43-8 phenyl 3-allyloxycarbonylamino-4-O-acetyl-2,3,6-trideoxy-1-sulfinyl-L-lyxo-hexopyranoside 
• 849071-44-9 phenyl 3-allyloxycarbonylamino-4-O-acetyl-2,3,6-trideoxy-1-thio-L-lyxo-hexopyranoside 
• 849071-48-3 phenyl 3-allyloxycarbonylamino-2,3,6-trideoxy-1-thio-L-lyxo-hexopyranoside 

Relevant academic research and scientific papers

A divergent approach to 3-azido-2,3,6-trideoxy-l-hexoses from rhamnal

An alternative strategy has been developed for producing 3-azido-2,3,6-trideoxy-l-hexoses, protected forms of daunosamine, ristosamine, acosamine, and epi-daunosamine. This method involved BF3·OEt2-induced peroxidation of rhamnal to

Syntheses and biological activities of 3′-azido disaccharide analogues of daunorubicin against drug-resistant leukemia

Anthracyclines, such as daunorubicin (DNR) and doxorubicin (Dox), are widely used for cancer therapy but are limited by drug resistance and cardiotoxicity. To overcome drug resistance, we synthesized a novel class of disaccharide analogues of DNR against